The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
This multicenter, real-world study confirms that RC48 alone or in combination with PD-1 inhibitors exerted a promising effectiveness and manageable safety for first-line, second- and post-line, and neoadjuvant therapy with la/mUC.
Authors
- Huimin Ge (ORCID: https://orcid.org/0000-0002-7509-1336)
- Chengquan Shen (ORCID: https://orcid.org/0000-0001-8402-2271)
- Ruize Qin (ORCID: https://orcid.org/0009-0004-8882-6030)
- Hu Ding (ORCID: https://orcid.org/0000-0002-1814-1552)
- Yanhua Wang (ORCID: https://orcid.org/0009-0005-4471-1554)
- Xinzhao Zhao
- Changxue Liu (ORCID: https://orcid.org/0009-0001-3368-6796)
- Yonghua Wang (ORCID: https://orcid.org/0009-0005-6099-307X)
- Hongyan Ge (ORCID: https://orcid.org/0000-0001-5566-4056)
- Xiaocheng Ma (ORCID: https://orcid.org/0000-0002-8258-8463)
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qingdao Center of Resource Chemistry and New Materials (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1186/s12967-025-06237-4
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- National Key Research and Development Program of China